Janssen/AbbVie drug approved in graft-versus-host disease
First use for Imbruvica outside blood cancer.
X
Janssen/AbbVie drug approved in graft-versus-host disease
https://pharmaphorum.com/news/imbruvica-drug-approved-graft-versus-host-disease/
graft versus host disease
Imbruvica granted fourth Breakthrough status
The drug is also granted Orphan Drug Designation by the FDA.
